PCSK9抑制剂的临床研究进展

Clinical Research Advances of PCSK9 Inhibitors

前白蛋白转化酶枯草菌素9(proprotein convertase subtilisin/Kexin type 9,PCSK9)是一种参与脂质调节的丝氨酸蛋白酶。PCSK9抑制剂是通过不同途径抑制PCSK9功能的物质。从2003年发现PCSK9基因突变到2015年两种PCSK9单克隆抗体上市的这个过程,是一个典型的从分子研究向临床成功转化的例子。本文就该领域临床研究进展做一系统综述。

Proprotein convertase subtilisin/Kexin type 9(PCSK9)is a serine protease involved in lipid regulation.PCSK9 inhibitors are substances that inhibit the function of PCSK9 through different pathways.The translation of discovering PCSK9 gene mutation in 2003 into launching two anti-PCSK9 monoclonal antibodies in 2015 serves as a successful example.We will systematically review the advances of clinical researches in this field.